Prelude Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Prelude Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-884	Closed	-$106K	–	2354
2019 Q3	$106K	Buy	884 +245	+38%	+$49.3K	﹤0.01%	937
2019 Q2	$191K	Buy	639 +351	+122%	+$146K	0.01%	747
2019 Q1	$130K	Buy	288 +7	+2%	+$3.06K	0.01%	843
2018 Q4	$128K	Buy	281 +135	+92%	+$83.7K	0.01%	863
2018 Q3	$132K	Sell	146 -18	-11%	-$11.9K	0.01%	896
2018 Q2	$97K	Buy	+164	New	+$107K	0.01%	937

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HWM

HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Prelude Capital Management's HTGM Position: Q4 2019 in Review

Prelude Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2019, closing a stake of 884 shares — an estimated $106K sold.

Prelude Capital Management first reported a position in HTGM in Q2 2018 and held it in 6 quarters. The position peaked at $191K in Q2 2019. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

Prelude Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Prelude Capital Management sold 884 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2019, an estimated $106K.
Prelude Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Prelude Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $191K in Q2 2019.
27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2019.

Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.